PVIVAX

Knowledge sharing for relapsing malaria

Search

  • P. vivax malaria
    • Malaria and P. vivax malaria
    • Symptoms & severity
    • Illness and mortality
    • Populations at risk
      • Pregnant women and children
      • Migratory populations
    • Role in malaria elimination
    • Lifecycle
    • Relapses
    • Vectors
  • Diagnosis & treatment
    • Diagnostic methods
      • Microscopy
      • Rapid diagnostic tests
      • Molecular methods & serology
    • Diagnosing severe vivax malaria
    • Treatment
      • Radical cure
      • Blood stage treatment
      • Liver stage treatment
    • G6PD Deficiency
      • G6PD Global Prevalence
      • G6PD diagnostics
      • Types of G6PD clinical diagnostic tests
  • Regions & countries
    • Africa
    • Eastern Mediterranean
    • South East Asia
    • The Americas
    • Western Pacific
  • In the field
    • Projects
    • Videos
  • Tools
    • Study database
  • Resources
  • News & events
  • About us
Map with highlighted countries to indicate where studies are taking place

P. vivax malaria studies:  A database of studies focusing on improving access to radical cure.

View the database

Photo: istock

About the P. vivax information hub 

Find out more
Photo: istock
Photo: Schumann/MMV

Video on life-changing treatment to cure relapsing P. vivax malaria.

Photo: Schumann/MMV

Featured resources

Close up of a womans face smiling.
28th October 2020

Malaria Day in the Americas 2020: Interview with Elisa Vidal on supporting countries to eliminate relapsing malaria

This Malaria Day in the Americas MMV’s Regional Adviser in Latin America, Elisa Vidal, talks about her work supporting countries to eliminate P. vivax malaria.

MMV
Videos
Image of a child in Brazil
13 Oct 2020

Life-changing treatment to cure relapsing P. vivax malaria

This film shows how MMV is working in partnership with other organizations to develop new tools to combat malaria in Brazil.

Videos
three pills of tafenoquine medicine next to glass pill jar
13 Oct 2020

Improving access to radical cure of P. vivax malaria in Thailand – produced by APLMA and APMEN

Animation by APLMA and APMEN outlining recent actions taken to improve access to radical cure in Thailand.

Videos
Photo: Sumon Yusuf

G6PD Operations Research Community of Practice

The Community of Practice is a collaboration of researchers, organizations, and clinicians committed to advancing the introduction and scale-up of G6PD diagnostics in support of safe access to radical cure treatment for Plasmodium vivax malaria through operations research.

1

News

Female laboratory technician performing microscopy

New single-dose medicine to prevent relapse of P. vivax malaria just approved in Peru

18 Jan 2021
Mother holding young child in Thailand

GSK, MMV filing for Kozenis (tafenoquine) in paediatric populations with Plasmodium vivax malaria accepted by Australian Therapeutic Goods Administration

08 Jan 2021
palm of hand face up holding dispersible tablets of tafenoquine

Study finds malaria drug can also prevent relapse in children

16 Dec 2020
crowd of children looking directly at the camera

GSK and MMV present positive data on treatment for Plasmodium vivax malaria in children from 6 months up to 15 years of age

19 Nov 2020
View news and events
1

Events

1

Publications

12 Jan 2021

Further evidence needed to change policy for the safe and effective radical cure of vivax malaria: Insights from the 2019 annual APMEN Vivax Working Group meeting

Varunika Sonani Hapuwatte Ruwanpura et al.
Asia & the Pacific Policy Studies
Peer-reviewed article
27 Jun 2020

Primaquine for Plasmodium vivax malaria treatment.

The main reason conventional primaquine regimens last 14 days is because this was the time taken to repatriate US military personnel by ship following active service in the Korean War.1 We therefore congratulate Walter Taylor and colleagues2 for finally upending an absurdly impractical 60-year-old legacy and setting a new standard of care. However, convincing policy makers and practitioners to implement this new standard of care presents challenges relating to how risk is perceived and managed.

Lancet
Peer-reviewed article
27 Jun 2020

Primaquine for Plasmodium vivax malaria treatment - Authors' reply.

We agree with Harin Karunajeewa and Robert James that radical cure of Plasmodium vivax malaria needs to be deployed more widely. The question is, how do we achieve this? Shortening the treatment course and thereby improving adherence is an important step in the right direction.1 Primaquine regimens are usually extended over 14 days to reduce the daily dose and thereby improve tolerability and safety. The main adverse event risk is haemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. The primary reason why the prolonged regimen is still recommended is the lack of G6PD testing in vivax-endemic countries.2 Novel point-of-care G6PD tests herald a new era, in which the use of different dosing regimens can be explored.

Lancet
Peer-reviewed article
26 Jun 2020

Presence of additional Plasmodium vivax malaria in Duffy negative individuals from Southwestern Nigeria.

Malaria in sub-Saharan Africa (sSA) is thought to be mostly caused by Plasmodium falciparum. Recently, growing reports of cases due to Plasmodium ovale, Plasmodium malariae, and Plasmodium vivax have been increasingly observed to play a role in malaria epidemiology in sSA. This in fact is due to the usage of very sensitive diagnostic tools (e.g. PCR), which have highlighted the underestimation of non-falciparum malaria in this sub-region. Plasmodium vivax was historically thought to be absent in sSA due to the high prevalence of the Duffy negativity in individuals residing in this sub-continent. Recent studies reporting detection of vivax malaria in Duffy-negative individuals from Mali, Mauritania, Cameroon challenge this notion.

Malar J
Peer-reviewed article
View all publications

Get in touch

Contact us.

Submit information

Subscribe

Follow us

  • Twitter
  • LinkedIn
  • Facebook
  • Disclaimer
  • Privacy policy
A Remora website by Manta Ray Media